Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 5/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30758878 | 1.00 | MEN1 (0.44) | MEN1KMT2ALMNAPOLBALDH1A1 | |
| SCHEMBL1536380 | 0.79 | CYP1A2 (0.44) | MEN1KMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL1096086 | 0.79 | PLAU (0.50) | ALDH1A1CASP1HSD17B10KDM4EMAPT | |
| SCHEMBL582273 | 0.79 | PLAU (0.56) | MEN1KMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL12336053 | 0.79 | TRPA1 (0.40) | MEN1KMT2ACYP1A2KDM4ECYP3A4 | |
| SCHEMBL1204965 | 0.79 | ROCK1 (0.58) | MEN1KMT2ALMNAPOLBROCK1 | |
| SCHEMBL8147969 | 0.79 | NR4A2 (0.43) | MEN1KMT2AALDH1A1CASP1CYP1A2 | |
| SCHEMBL1204569 | 0.79 | MAPT (0.43) | MEN1KMT2ALMNAPOLBALDH1A1 | |
| SCHEMBL1562651 | 0.79 | CYP2A6 (0.53) | MEN1KMT2ALMNAPOLBALDH1A1 | |
| SCHEMBL30738206 | 0.79 | MAPT (0.43) | MEN1KMT2ALMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386511-B2 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-03-20 | — | — | EP | claimed |
| EP-2106212-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, Inc. (US) | 2009-10-07 | — | — | EP | claimed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | claimed |
| WO-2008091555-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-07-31 | — | — | WO | claimed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | disclosed |
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | disclosed |
| US-9078888-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| WO-2011140228-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| EP-2106212-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, Inc. (US) | 2009-10-07 | — | — | EP | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008091555-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008091555-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | ESRRB, ESRRG, ESRRA | MEN1 4759/4885KMT2A 2488/4885LMNA 1686/4885 |
| US-20090030036-A1 | Nuclear receptor binding agents | NR0B1, NR2E3, NR0B2 | MEN1 3769/4885KMT2A 3860/4885LMNA 3493/4885 |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | FABP1, FABP4, ADIPOR2 | MEN1 3741/4885KMT2A 3575/4885LMNA 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.